Patient]. A 35-year-old woman with a history of type-I diabetes mellitus since age 8 and diabetic nephropathy was evaluated for participation in a study of the relationship between levels of advanced glycation and renal-vascular complications of diabetes. Five years ago, uncontrolled diabetes (hemoglobin Al 11%) had been accompanied by mild hypertension, background retinopathy, proteinuria (1.5 g/24 hr), creatinine clearance 90 ml/min/1.73 m2, and an elevated serum cholesterol.
chronic renal failure secondary to chronic pyelonephritis and hypertension had been treated with hemodialysis for one year. She was admitted to a study of the long-term effects of intensive hemodialysis on circulating levels of AGE-modified proteins and lipoproteins, known to be elevated in non-diabetic patients with end-stage renal disease (ESRD). At that time, the patient had a blood pressure of 165/100 mm Hg; pulse, 68 and regular; serum creatinine, 3.2 mg/dl; Hb Al, 4.1%; Hb-AGE, 5.5 U/mg; and serum AGE, 88 U/ml (normal range 3-20 U/mI). Her serum LDL apolipoprotein B was elevated at 96 mg/dl, as was AGE-ApoB at 288 U/mg ApoB. Following a two-month period of therapy on a high-flux hemodialyzer (AN69), her Hb Al and Hb-AGE were still within normal limits (3.6% and 4.0 U/mg, respectively). Total serum AGE was 60 U/mI and AGE-ApoB, 210 U/mg ApoB.
Interestingly, serum LDL ApoB had fallen to within the normal range (50 mg/dl). Discussion DR. HELEN VLASSARA (Professor and Head, Laboratory of Diabetes and Aging, Picower Institute for Medical Research, Manhasset New York): These two cases represent typical examples of advanced renal failure due to widely different causes, long-standing diabetes and chronic pyelonephritis. We know that diabetic nephropathy afflicts 35% to 45% of patients with insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) with similar pathologic characteristics [1, 2] . We also know that all nephropathies, independent of causality, ultimately converge onto a common downward course of glomerular sclerosis associated with renal failure [1] [2] [3] . Diabetic nephropathy now is the single most common cause of ESRD in the United States, accounting for more than 30% of all ESRD patients [4] . According to the United States Renal Data System (USRDS), the survival of diabetic patients treated with some form of dialysis is greatly reduced compared with that of non-diabetic patients. Two-year survival rates are 5 1.4% for non-diabetics and 43.9% for diabetics, respectively. On the other hand, for diabetics with renal transplants, the 2-year survival rate is 88.1%, which in fact, is almost identical to the overall survival of 88.4%. This similarity points to a significant advantage of renal transplantation therapy for diabetic and nondiabetic patients alike. Persistent hyperglycemia is a prerequisite for tissue and end-organ damage in diabetes mellitus [5] . Much recent evidence has linked chronic hyperglycemia to the accumulation of the late products of glucose-protein interaction, called "advanced glycation end products" (AGEs), and to a variety of late complications, including diabetic nephropathy [6, 7] . A similar, but slower accumulation of AGEs occurs normally with aging [6, 7] . We have reported that circulating and arterial tissue AGE levels increase dramatically in diabetic as well as in non-diabetic patients with ESRD [8, 9] ; this finding has been confirmed by other laboratories [10, 11] and has been extended to include elevated levels of specific AGE-modified serum proteins, such as AGE-lipoproteins [12] and microglobulin [13, 14] both in diabetic and non-diabetic uremic patients. Today, I will focus on some novel insights into mechanisms of tissue damage in renal disease of diabetic or non-diabetic etiology, which may provide a rationale for new and better therapeutic interventions.
The elusive nature of AGEs
The emergence of AGEs resulting from the spontaneous reaction between glucose and proteins-herein referred to as "first generation" AGE-occurs most noticeably on long-lived structural proteins [15, 161 . A significant correlation has been shown between the levels of these irreversible modifications and the presence and severity of diabetic complications [7, 11] .
The structural elucidation of specific AGEs remains a problem, stemming largely from their heterogeneity and tendency to be unstable during isolation. A few such adducts have been structurally identified thus far through the use of a variety of direct or indirect criteria, including 2(2-furoyl)-4(5)-(2-furanyl)-1 H-imidazole (FF1), alkyl-formyl-diglycosylpyrrole (AFGP), pyrraline, carboxy-methyl-lysine (CML), and pentosidine [6, 7, 171 . Two epimers of a new lysine-lysine cross-linking structure incorporating two moles of carbohydrate, named "crosslines A and B," were isolated from in-vitro incubations, but not as yet from in-vivo sources [18] .
Sensitive and specific immunochemical methods in the meantime have supported the in-vivo existence of structurally related compounds, although the precise structural features of dominant "native" AGEs remain elusive. An important feature of the anti-AGE antibodies generated against AGEs prepared in vitro under physiologic conditions [19] [20] [21] has been the identification of an apparently major class of cross-reactive AGE epitope(s) that are common to proteins modified by AGE in vivo, and which includes AGEs that are inhibited by aminoguanidine, a pharmacologic inhibitor of advanced glycation [22] .
A close correlation exists between AGE formation and the physicochemical changes taking place on connective tissue in diabetes or in aging, including collagen-to-collagen cross-linking and tissue rigidity [6, 7] . Furthermore, AGE-mediated cross-link formation decreases the solubility and susceptibility of proteins to enzymatic digestion. These properties are particularly relevant to the function of connective tissue and extracellular matrix collagen, as they are associated with increases in thickness, rigidity, and breaking time, changes typically observed in diabetic and in aging tissues. In addition, AGE moieties formed on matrix components, such as on vessel wall and kidney, retain their ability to cross-link and trap a variety of plasma proteins, most notably lipoprotein and immunoglobulins [6, 7] .
Advanced glyclation end products formed in vascular matrix might interfere chemically with the action of nitric oxide (No.), the active constituent of endothelium-derived relaxing factor (EDRF) [23] . This possibility implicates AGEs in the defective vascular relaxation and hypertension associated with both diabetes and aging [24] [25] [26] .
In-vitro studies have demonstrated that collagen-bound AGE moieties react directly with nitric oxide to inactivate it [23], while in experimentally induced diabetes, defective vasodilatory responses develop in a pattern consistent with the quenching of nitric oxide by AGEs at the subendothelial level. Further confirmatory evidence for the role of AGEs as modulators of vascular tone in diabetes came from our study of the effect of exogenous administration of AGE-modified proteins to non-diabetic animals [271. Significant impairment of vasodilation occurred in AGEtreated normoglycemic rats and rabbits; this effect was diminished by the AGE inhibitor aminoguanidine.
Endothelium-derived nitric oxide also exerts potent borneostatic and antiproliferative effects on different cell types and has been proposed to be essential for the mitogenic quiescence of subendothelial vascular smooth muscle cells. AGE-modified matrix proteins specifically block the antiproliferative effect of nitric oxide on cultured vascular smooth muscle cells and renal mesangial cells in vitro [281. These data implicate tissue AGEs as important modulators of nitric oxide-mediated responses; however, further studies are required to confirm the role of NO • in the evolution of the proliferative vascular and glornerular lesions present in diabetes mellitus.
Dyslipidemias characterized by various patterns of increased levels of LDL, VLDL, and IDL are not only common in diabetics and uremics with or without diabetes, but also increase the likelihood that these patients will suffer from the atherosclerotic complications of heart attack and stroke. Low-density lipoprotein is the major lipoprotein component responsible for transferring both exogenously absorbed and endogenously synthesized lipids to peripheral tissues. Biochemical modifications that affect the structural and functional integrity of LDL are believed to be central to atherogenesis. In addition to the oxidative modification that affects the clearance of LDL, a new class of chemical modifications, which can render it more atherogenic, results from advanced glycation [29] .
Clinical studies indicate an increased level of AGEs on LDL obtained from diabetic compared to normal individuals [12, 29] . Of note, AGE moieties were present on both the apoprotein and lipid components of LDL. ApoB-AGE levels were increased more than twofold in the diabetic samples, and lipid-AGE levels were elevated almost fourfold in diabetic patients [12, 29] . It is interesting that LDL isolated from diabetic individuals displayed an increased oxidative modification as well [29] . It is unclear whether these values reflect an increase in lipid oxidation in vivo, or simply an increase in the susceptibility of LDL to oxidation after it is removed from plasma. Nevertheless, these data indicate that LDL oxidation occurs concomitantly with advanced glycation and that AGE formation might be a primary mechanism responsible for the pathogenetic modification of the LDL particle.
Indeed, the presence of amino groups on phospholipids such as phosphatidylethanolamine and phosphatidylserine suggests that glucose could react directly with lipid amines to form AGEs. The intermolecular oxidation-reduction reactions, known to occur during advanced glycation, might then oxidize fatty acid residues independently of the transition metals or exogenous, free-radicalgenerating systems that have frequently been added in experimental studies. When free-amine-containing phosphatidylethanolamine was incubated with glucose and metal chelators, AGEs as well as oxidation products formed as a function of glucose concentration [29] . Both processes were effectively prevented in the presence of the AGE inhibitor aminoguanidine. Of note, lipids lacking free amines, such as phosphatidylcholine, were not able to react with glucose, nor could they form oxidation products; this fact points to amine-glucose interactions as a primary mediator of fatty acid oxidation in vivo.
AGEs interact with cellular receptors to elicit multiple effects
In the last decade, our understanding of the biology of AGEs has expanded significantly. Given the abundance of AGEs in both the extra-and intravascular compartments, studies probing the complex cellular interactions with AGEs have yielded new insights regarding the pathogenetic aspects of this ubiquitous process. Initially, it was observed that both in-vivo formed and in-vitro synthesized AGEs are recognized by distinct macrophage AGE receptors [30, 31] . Two AGE-binding proteins (60 kD and 90 kD) isolated from rat liver membranes were identified on rat monocyte/macrophage surfaces [32] . These proteins were recently found to be homologous to OST-48 [33] and 80 K-H [341, respectively [351. Specific antisera raised against these two AGEreceptor proteins subsequently confirmed a related pattern of receptor expression and properties on cells other than rat macrophages (for example, vascular endothelium, mesangium) as well as in species other than rat (for example, mouse and human), probably pointing to a highly conserved family of proteins (Table  1 ). Based on the range of cellular responses thus far associated with AGE-receptor/ligand interactions, for example, monocytic migration, activation, and cytokine and growth factor secretion, a regulatory system has begun to emerge via which macrophages, while selectively removing AGE-modified macromolecules, also can participate in repair/remodeling processes [36, 37] .
Other members of the hemopoietic lineage subsequently were found to express these molecules on their surface. Of particular interest, resting human and rat CD4+ and CD8+ T-cells were found to constitutively express such sites and to bind AGE proteins, whereas phytohemagglutinin (PHA) prestimulation of T-cells resulted in AGE receptor upregulation and in IFNy synthesis and release [38] . These results suggest that AGEactivated IFNy-producing T-cells may contribute to tissue damage in cooperation with primed macrophages. This concept is consistent with evidence that activated lymphocytes found in atherosclerotic lesions might be active participants in an immune-like response underlying atherogenesis [39] . Within vascular tissues, AGE accumulation might serve as a primary stimulus for tissue macrophage and T-cell activation in such lesions.
Additional cell-surface-binding proteins for AGE determinants have been identified and cloned from other tissues and cells of interest, for example, endothelium [40] [41] [42] . These proteins include a novel 35 kD member of the immunoglobulin superfamily of receptors, named RAGE, and an 80 kD protein, with complete sequence homology to lactoferrin (LF). Using immunohistochemical and in-situ hybridization techniques, Brett et al found RAGE expression to be localized to monocytes and a variety of tissues, including neural tissues and skeletal and smooth muscle [43] .
Another molecule has recently been added to the AGErecognizing proteins. A 32 kD protein, now referred to as galectin-3, but previously known as Mae-2 or carbohydrate binding protein-35 (CBP-35), is expressed on macrophages and other cells and exhibits high-affinity binding for AGE ligands (Kd, 3.5 X io M') compared with that of other carbohydrates (1 X i0 M1) [44] . Binding of AGE to galectin-3 occurs within the 18 kD C-terminal peptide and promotes high-molecular-weight complex formation with the AGE ligand and with other membraneassociated receptor molecules on the cell surface. The significance of this finding is under investigation.
The protein sequence, ligand specificity, and functional differences between these molecules and the macrophage AGE-binding polypeptides I have described have led us to speculate that there may exist a number of AGE-binding proteins with or without "receptor" characteristics that might contribute to diverse cellular functions, for example, chemotaxis, adhesion, activation, cell growth and differentiation, but also to clotting or vascular harrier Cell type integrity. In this context, in-vitro evidence indicates that AGEendothelial cell interactions result in increased endothelial cellassociated procoagulant activity and vascular permeability [40] .
Of particular relevance has been the identification of murine and human mesangial cell AGE-binding sites [45, 46j. An important function of this group of mesangial cell AGE-receptors probably is the regulation of extracellular matrix (ECM) synthesis and secretion. Exposure of cultured mouse mesangial cells to AGE-BSA results in a receptor-mediated upregulation of mRNA and protein secretion of matrix proteins, for example, al type-IV collagen and laminin A, Bi, and B2. Of note, the collagen alIV mRNA increase initiated by the AGE receptors appeared to be mediated, at least in cultured cells, by PDGF [46] .
AGEs and the kidney: Animal and human studies
Despite the mounting in-vitro evidence, only recently did direct in-vivo evidence elucidate the pathogenetic influence of AGE receptor-ligand interactions. Studies in normal rats and rabbits demonstrated that the short-term administration of homologous AGE albumin prepared in vitro can reproduce vascular defects similar to those observed in culture as well as to those associated with experimental diabetes, including vascular leakage, or unresponsiveness to vasodilatory agents [27] . We subsequently attempted to determine the direct contribution of cellular AGE-dependent responses to the intact glomerular structure in vivo by examining selected molecular events involved in mesangial cell responsiveness, such as the induction of ECM or growth factor genes [47] . The study focused on microdissected glomeruli following the injection of AGE-mouse serum albumin (MSA) for 4 weeks and using competitive polymerase chain reaction (PCR) assays to quantitate specific ECM gene alterations. We observed a predominant increase in al type-IV collagen and laminin BI mRNA only in the mice receiving AGE-modified MSA [47] . Of note, the mRNA of another growthpromoting molecule, TGF-pl, was significantly increased in the AGE-treated mice [47] . Prolonged administration of AGEs to nondiabetic rats resulted in glomerular hypertrophy, basement membrane thickening, and mesangial ECM expansion consistent with frank glomerulosclerosis (Fig. 1) , which was associated with significant proteinuria and albuminuria [48] . Similar administration of AGE to euglycemic rabbits induced substantial structural changes in the aortic wall, such that atheroma formation was vastly accelerated after a 10-day exposure to exogenous hyperlipidemia [49] . In all these studies, treatment with aminoguanidine largely ameliorated the AGE-mediated pathology [27, 47, 48, 49] .
All the foregoing evidence led us to speculate that the AGEreceptor system represents a principal degradation mechanism for AGE-modified tissue and cell components, capable of generating small soluble AGE peptides and amino acids which, combined with normal proteolysis of matrix components, gives rise to a class of circulating, low-molecular-weight AGE-modified substances. Levels of these substances likely depend on the underlying tissue AGE levels and the activity of AGE receptor-and non-receptordependent removal systems. The degradation products of AGEmodified proteins presumably are carried into the circulation to be cleared by the kidneys in a clearance-dependent manner, since in serum, the levels of AGE peptides correlate with renal function [8, 9, 11] . In normal individuals, renal clearance of AGE peptides is estimated to be 0.72 ml/min [91. Diabetic individuals with normal renal clearance also can clear AGE peptides at the same rate; however, progressive loss of renal function is associated with increasing circulating AGE levels, up to eightfold in diabetic patients with ESRD [8, 9] .
Diabetic patients with renal disease are far more susceptible to cardiovascular complications, mostly because of accelerated atherosclerosis [4] . The pronounced increase in AGE degradation products in the circulation of diabetic anephric patients has raised the possibility that uncleared recirculating AGEs include a class of potentially reactive, and therefore "toxic," intermediates. This "toxic" potential was in fact suggested by in-vitro studies showing that small-size AGE peptides, when isolated from human serum or proteolytically produced from in-vitro formed AGE albumin, become covalently incorporated into target proteins, such as normal collagen or low-density lipoprotein (LDL), producing AGE collagen [9] and AGE LDL [12] .
The in-vitro studies presented have generated a search for in-vivo evidence of the "reactivity" of AGE peptides. These attempts, for instance, have measured levels of AGEs incorporated on plasma proteins, such as ApoB LDL, a highly atherogenic macromolecule, or /32-microglobulin from patients with renal failure with or without diabetes (Fig. 2 ). Marked elevations in AGE Apo B were found in plasma samples from diabetic as well as non-diabetic patients with renal failure, compared to normals, and diabetics with normal renal function [12] . Such AGE modification of LDL delays clearance by the classic human LDL receptor [12] . Miyata and colleagues provided further support for the in-vivo "reactivity" of AGE peptides when they reported abnormally high AGE-modified f32-microglobulin in serum and urine of nondiabetic patients with hemodialysis-associated amyloidosis [13, 14] .
The human and animal studies together point to an important "side effect" of the in-vivo fate of AGE-modified proteins and lipids, which might be due either to AGE receptor-or nonreceptor-dependent mechanisms: the catabolic products of AGE macromolecules include reactive substances which, if not eliminated by the kidney in a timely manner, can irreversibly alter susceptible renal and extrarenal structures, producing "second" or "third" generation AGEs. Thus, uncleared, reactive AGEs might prove important potentiating factors of tissue damage ( Table 2) .
Novel therapeutic approaches
In 1986, the small nucleophilic compound aminoguanidine was shown to be a potent and specific inhibitor of glucose-mediated cross-linking and tissue damage in vivo [22] . The terminal amino group of aminoguanidine, by virtue of its low pKa, reacts specifically with glucose-derived reactive intermediates and prevents protein-protein or protein-lipid cross-links from forming. Experimental studies affirmed this mechanism of action of aminoguanidine. A number of studies subsequently have demonstrated an efficacious role for aminoguanidine in preventing either AGE formation or diabetes-related complications in vivo in experimental animals [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] . Diabetic rats treated with aminoguanidine, for example, exhibit significantly less collagen-linked fluorescence and cross-linking in the vascular wall than do untreated diabetic controls [52, 58, 63] markedly inhibits advanced glycosylation and the AGE-mediated A limited but encouraging amount of information has been tissue damage that occurs during chronic hyperglycemia. Ami-obtained from a small 28-day, double-blind, placebo-controlled noguanidine has displayed little toxicity so far in clinical studies, human trial of aminoguanidine [65] . Measurements of the "late" and trials aimed at evaluating its efficacy for a variety of diabetic glycation products formed on hemoglobin (Hb-AGE), relative to complications are underway in the United States and Europe.
the "early" product or Amadori compound, referred to as HbAIC, DR. VLASSARA: Let me address the first question, which dealt with the factors that determine susceptibility of proteins or lipids to modification by AGEs. The rate and the degree of modification that occur on any given protein has to do with a number of parameters; the number of available amino groups, the position of these amino groups, the microenvironment in which they exist, the charge, pH, and the buffering capacity of the microenvironment all greatly influence the rate by which the glucose-protein reactions occur. Also, the life span of the protein is very important: the longer the half-life of a protein, the greater its chances for reacting with ambient glucose (for example, collagen, lens crystallins, and myelin proteins).
Your second question had to do with the small-sized AGE substances found in the circulation. These are small molecules, between 2000 and 6000 daltons, and are believed to reflect the constant influx from the tissues and from cellular debris, which is ultimately cleared by the kidneys. Advanced glycation end products are found in the urine in substantial quantities as long as renal clearance is more or less intact. We do not know very clearly all the factors that may determine the movement of small AGEs from the tissues into the bloodstream. One might consider first the same factors that dictate the passage of any catabolic products 
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of proteins or lipids from the tissue and extracellular compartments through the lymph and the blood to their final elimination. Other factors include the rate of AGE formation, the efficiency of natural AGE removal mechanisms, for example, receptor-mediated and extracellular proteolysis. Also, the rate at which AGEs are excreted in the urine ultimately might be determined by how reactive they are and by whether they will interact with other proteins and cell surfaces as they pass through. Of note is the recent observation that as kidneys age, the AGE clearance decreases markedly [66] ; this finding implies that the aging kidney is less able to filter them.
DR. MADIAS: Can you show in the aging animal or in the aging human that the level of these AGEs increases in serum?
DR. VLASSARA: Yes, we recently obtained evidence that circulating AGEs increase in non-diabetic, senescent rats, although it is difficult to demonstrate dramatic increases in serum until the renal function declines significantly. To my knowledge, such studies have not been done in humans.
DR. MADIAs: So aging itself without accompanying, independent renal disease is associated with increased levels of AGE compounds? DR. VLASSARA: Tissue AGEs accumulate with age before registering declining renal function. High serum AGEs, however, are still technically difficult to detect in the absence of renal disease. In the rats used in our study, renal function declined with age [66] ; this decline might explain our findings. We have not yet completed similar studies carried out in elderly patients. nents of the AGE receptor described thus far, p90, p60, and galectin-3, a well characterized surface activation marker. In response to exposure to high levels of extracellular AGEs, these cells produce growth factors and, as we have shown, a number of key extracellular matrix components [7, [46] [47] [48] . It is highly probable that these receptors play a role not only in normal renal development, but also in glomerular injury. In terms of adverse effects that have been noted, a temporary elevation of liver function tests in these patients, occurring infrequently in the first two months, is apparently transient and mild. The patients are maintained on the medication. The second side effect has been a transient reduction in hematocrit in certain cases. There has not been any major concern about these findings up to now. Dr. Williams, would you like to add anything to this? Your presentation emphasized the importance of renal dysfunction in the rise of small AGE compounds in the circulation. Would you elaborate further on where toxicity might arise from these smaller-molecular-weight AGEs, which would be cleared normally by the kidneys? Why should they be toxic in comparison to the more complex AGEs that you mentioned? What is the fate of the low-molecular-weight AGEs with regard to receptor uptake? How would you predict they might affect tissue function and cause tissue damage? DR. VLASSARA: The chemistry of AGEs is indeed complex, and relatively few compounds are known as biologically important. Notoriously difficult to isolate and purify, AGEs remain vastly heterogeneous as a class. Many AGEs at their final stages reflect irreversible cross-links, or permanent "locks" between a reactive glycation intermediate attached on one peptide and an amino group that belongs to another protein or peptide. Once the cross-link is formed, the AGE produced can be referred to as a no-longer-reactive glycation product, usually linking up two or more peptides of various sizes. Small AGE peptides are thought to represent cleavage products generated as a result of normal proteolysis of tissue proteins, which can contain reactive or non-reactive AGEs. Normal tissue turnover and repair systems degrade glycated proteins, partially hydrolyzing the modified proteins and releasing low-molecular-weight peptides, bearing a plethora of "reactive" intermediates in addition to the nonreactive AGEs. This class of still chemically active intermediates will cross-link to tissue and plasma proteins, if they are not excreted efficiently in the urine, to form "second-" and "third-generation" AGEs. Thus, in the presence of progressive renal impairment, uncleared AGEs reach high levels. Such high concentrations of AGEs in tissues and in the circulation can be considered "toxic" in view of the multiple adverse cellular and tissue responses elicited via the AGE-receptor system or via direct chemical impact.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): I'm interested in factors that determine the variability of tissue and serum levels of AGEs in diabetic subjects and the relationship among these factors and susceptibility to vascular complications. Particularly, I'm interested in the nephropathy. As you know, only 30% to 40% of type-I diabetics develop nephropathy, and glucose levels appear to be only part of the explanation. In particular, have there been analyses of stored blood samples to determine the relationship between serum AGE levels and diabetic complications? DR. VLASSARA: Several recent studies have determined a close relationship between tissue AGEs, especially in skin, and stage of development of a number of complications [11, 17] . We have recently obtained preliminary evidence pointing to a similar correlation between plasma proteins, for example, ApoB-LDL and severity of macrovascular disease in diabetic and non-diabetic individuals with or without nephropathy [121. There is no doubt that glycemic control is a major, but not the sole, key factor in diabetic nephropathy. Epidemiologic data clearly suggest that genetically determined susceptibilities exist, the expression of which may depend on abnormal biochemical events, namely, excessive AGE formation.
DR. LEVEY: What are some of the factors that determine the variability in tissue and AGE levels within diabetics? DR. VLASSARA: Of course, poor glycemic control with long-term sustained hyperglycemia accelerates the rate of AGE formation and deposition within the tissues. Another determinant of tissue burden of AGEs is now believed to be the abundance and level of efficiency of the cellular AGE-receptor system. It is anticipated that individual differences that are genetically determined exist regarding this important mechanism for removal and degradation of AGEs. A recently recognized, and perhaps the most critical, factor determining total-body AGE burden is renal function, as discussed today. The last two factors are subject to genetically determined susceptibilities to dysfunction, thus far unidentified, yet actively investigated.
DR. BRIAN PEREIRA (Division of Nephrology, New England Medical Center): Which component of AGE does your assay detect? I presume that assays are picking up a wide range of AGEs, some linked to proteins, lipids, etc. DR. VLASSARA: The assays that we have referred to so far included first a radioreceptor assay, which was based on AGE recognition by the AGE receptor of intact macrophages. We no longer use that assay because it was quite cumbersome. The currently used assay is based on an AGE-ELISA system that utilizes well-characterized polyclonal antibodies, and more recently monoclonal anti-AGE antibodies. Regarding the precise structure of the AGEs that these assays recognize, it is extremely difficult to tell. Neither antibody recognizes any of the known AGEs, including FF1, pentosidine, pyrraline, AFGP, etc. We suspect that although both these antibodies recognize AGE structures that exist in vivo and that are biologically relevant, there might not be such a thing as a single, biologically important AGE structure. DR. PEREIRA: The reason I ask is because of the studies that you conducted on dialysis membranes. A synthetic membrane, F8, is not really a conventional membrane, while the commonly used AN69 happens to be a highly negatively charged membrane. I believe that adsorption and filtration need to be evaluated separately while studying clearance of AGEs by dialysis membranes. DR. VLASSARA: You are correct. In in-vitro studies on AGE mass balance performed on these two high-efficiency, biocompatible dialysis membranes by Dr. Steven Fishbane (Winthrop-University Hospital, New York), a greater degree of adsorption (threefold) was exhibited by the high-flux AN69 filter, which was independent of an equally greater filtration rate [68] . As far as we know, this was the first true comparison between low-flux and high-flux dialyzers, where the issue is focused on the clearance of larger molecules, for example, AGE peptides. DR. VLASSARA: Although aminoguanidine is capable of inhibiting nitric oxide synthase very well, it would appear that it does so at much higher concentrations than those used in in-vivo studies.
Thus this effect has not presented itself as a problem as yet. However, as we gather more information and experience from in-vivo studies, our conclusions might have to be adjusted accord- DR. VLASSARA: Yes. During glycation of the apoprotein or the lipid particle of LDL, oxidation-reduction rearrangements occur that can generate free radicals sufficient to induce fatty acid oxidation. Consistent with this, a close correlation was found between AGE modification and oxidation of LDL in vitro, as well as in vivo in patients with diabetes and/or renal failure. Accordingly, aminoguanidine protects not only against AGE, but also against oxidative modification of LDL, thus expanding its therapeutic spectrum against atherosclerosis.
